Email "Boehringer Ingelheim and Lilly announce positive top-line Phase III data results for empagliflozin as adjunct to insulin in type 1 diabetes" to a Friend.

Your Friend's Email Address:

Your Name:

Your Email:

Enter the word "" without the quotes:

By submitting, you agree to Becker's Healthcare terms of service and privacy policy.